Start Time: 16:30 January 1, 0000 5:28 PM ET Stryker Corporation (NYSE:SYK)Q1 2024 Earnings Conference CallApril 30, 2024, 16:30 PM ET Company Participants Kevin Lobo – Chair and CEOGlenn Boehnlein – VP and CFOJason Beach – VP, Finance and IR Conference Call Participants Robert Marcus – JPMorganLawrence Biegelsen – Wells Fargo SecuritiesRyan Zimmerman – BTIGJoanne…
gorodenkoff/iStock via Getty Images Stryker (NYSE:SYK) is a leading medical technology company with a diversified product portfolio. Target markets include orthopedics, spine, surgical instruments, neurotechnology, and medical and surgical equipment. Stryker has a strong position within robotics for orthopedic surgery and is also demonstrating solid growth across its other businesses. While the company’s valuation has…
Stryker Corporation (NYSE:SYK) Q4 2023 Earnings Conference Call January 30, 2024 4:30 PM ET Company Participants Kevin Lobo – Chair and Chief Executive Officer Jason Beach – Vice President-Investor Relations Glenn Boehnlein – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Lawrence Biegelsen – Wells Fargo Ryan Zimmerman – BTIG Joanne Wuensch –…
gorodenkoff I initiated Stryker (NYSE:SYK) in August 2023, and pointed out that Mako would continue to be a growth driver for the company. They reported a strong Q3 FY23 result and provided an initial FY24 guidance with 10%+ organic revenue growth. The Mako shoulder and spine applications are on track, and I think they are…
Stryker Corporation (NYSE:SYK) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 1:20 PM ET Company Participants Glenn Boehnlein – CFO Jason Beach – Head, IR Conference Call Participants Vijay Kumar – Evercore ISI Vijay Kumar Stryker this afternoon. We have Glenn Boehnlein, CFO; and Jason Beach, who heads Investor Relations. I’m Vijay Kumar, I…
jitendrajadhav/iStock via Getty Images We are initiating Stryker (NYSE:SYK) with a hold rating. This is a high-quality company with a solid history of growth, high margins, and stable returns. However, we believe the company is slightly overvalued, and better opportunities exist elsewhere. We recently wrote about other healthcare companies that seem to be offering better…